About immunitybio - IBRX
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
IBRX At a Glance
ImmunityBio, Inc.
3530 John Hopkins Court
San Diego, California 92121
| Phone | 1-844-696-5235 | Revenue | 113.29M | |
| Industry | Pharmaceuticals: Major | Net Income | -351,398,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 668.315% | |
| Fiscal Year-end | 12 / 2026 | Employees | 691 | |
| View SEC Filings |
IBRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.077 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.079 |
| Enterprise Value to Sales | 21.397 |
| Total Debt to Enterprise Value | 0.348 |
IBRX Efficiency
| Revenue/Employee | 163,947.902 |
| Income Per Employee | -508,535.456 |
| Receivables Turnover | 2.658 |
| Total Asset Turnover | 0.256 |
IBRX Liquidity
| Current Ratio | 5.099 |
| Quick Ratio | 5.084 |
| Cash Ratio | 3.932 |
IBRX Profitability
| Gross Margin | 85.631 |
| Operating Margin | -225.997 |
| Pretax Margin | -310.366 |
| Net Margin | -310.181 |
| Return on Assets | -79.427 |
| Return on Equity | N/A |
| Return on Total Capital | -102.092 |
| Return on Invested Capital | -112.103 |
IBRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 245.401 |
| Total Debt to Total Assets | 168.295 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 242.703 |